



BIOSENSORS
INTERNATIONAL

NEWS RELEASE

Biosensors Reports Second Quarter Results

*Continued Strength in Sales of Drug-Eluting Stents
Drives Product Revenue Growth of 89% over 2nd Quarter of Last Fiscal Year*

Singapore 11 November 2008 - Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP) today announced financial results for the second quarter of fiscal year 2009 ("2Q FY09") and the fiscal six-months ended 30 September 2008 ("1H FY09").

Total revenue, including revenue from licensing and royalties for the quarter, was US\$18.0 million, an increase of 95% from US\$9.2 million in the corresponding quarter for the last fiscal year ("2Q FY08"). In 2Q FY09, sales of drug-eluting stents increased to US\$8.2 million, representing a US\$7.0 million or 553% increase over 2Q FY08 and a US\$1.0 million or 14% increase over 1Q FY09 reported three months ago. The Company also reported a 27% increase in sales of other interventional cardiology products to US\$6.1 million over the US\$4.8 million reported in 2Q FY08. This increase is primarily attributable to continued growth in sales of bare-metal stents in the Japanese and European markets. For 2Q FY09, revenues from sales of critical care products were comparable to critical care product revenues achieved in 2Q FY 08. Drug-eluting stent sales growth experienced by one of the Company's licensees resulted in increased licensing revenues for the Company in 2Q FY09.

In 1H FY09, total revenue was US\$76.0 million, a 222% increase from US\$23.6 million in the prior year period ("1H FY08"), primarily attributable to US\$40.0 million received as one-time licensing revenue from Terumo Corporation. During 1H FY09, total product revenues were US\$34.2 million compared to US\$18.3 million for 1H FY08, an increase of 86%. Drug-eluting stent revenues for 1H FY09 were US\$15.4 million, more than four times the drug-eluting stent revenue of US\$3.6 million achieved in 1H FY08. Other interventional cardiology product revenues also grew significantly, increasing by 42% to US\$12.9 million from US\$9.1 million in 1H FY08. Critical care product sales showed a modest increase, growing by 4% to US\$5.8 million compared to US\$5.6 million in 1H FY08.

Mr. Mike Kleine, CEO and President said, "We continue to achieve our primary goal of revenue growth, particularly as it relates to the sale of BioMatrix™ stents. I am pleased with sales of more than US\$15.0 million in BioMatrix during the first six months following our commercial launch. Not only are we achieving our sales targets for BioMatrix but we also continue to meet our operational and clinical milestones. Our recent presentation of 12-month LEADERS data at Transcatheter Cardiovascular Therapeutics ("TCT") 2008 generated a tremendous amount of interest in our technology. This quarter we have also received regulatory approvals in key geographies such as India and Brazil, and our

operations team continues to meet product demand. Finally, Biosensors is actively implementing several measures, such as our US restructuring and the closure of our Netherlands-based manufacturing facility, to better align our expenses with efforts that more directly drive growth and profitability.”

In 2Q FY09, research and development (“R&D”) expenses, which include costs for new product development and testing, clinical trials, patent registration and regulatory approval, were US\$5.5 million compared to US\$5.9 million in 2Q FY08. In 1H FY09, R&D expenses were US\$12.6 million compared to US\$13.1 million in 1H FY08. The decrease in R&D expenses for the quarter and half year were mainly due to decreased clinical trial expenses in Europe and reduced professional service fees incurred.

Sales and marketing expenses were US\$7.2 million in 2Q FY09 compared to US\$4.9 million in 2Q FY08 and were US\$13.1 million in 1H FY09 compared to US\$8.4 million in 1H FY08. The increases were due mainly to expenses incurred for the commercial launch of BioMatrix, increased personnel costs associated with the expansion of the sales and marketing function in Europe and post-approval clinical activities for BioMatrix.

General and administrative expenses were US\$5.3 million in 2Q FY09 compared to US\$4.1 million in 2Q FY08 and totaled US\$11.0 million in 1H FY09 compared to US\$8.6 million in 1H FY08. The increase was mainly attributable to additional personnel and travel costs related to key management personnel, increased non-cash share-based option expenses, and higher professional fees associated with the infrastructure necessary to support the increased business activities.

In 2Q FY09, the Group reported a net loss of US\$17.7 million or 1.68 US cents loss per basic and diluted share, compared to a net loss of US\$11.0 million or 1.19 US cent loss per basic and diluted share in 2Q FY08. In 1H FY09, the Group reported a net loss of US\$1.2 million or 0.12 US cent loss per basic and diluted share compared to a net loss of US\$3.0 million or 0.33 US cent loss per basic and diluted share in 1H FY08. The decrease in net loss for the six-month period was mainly due to the non-recurring receipt of US\$40.0 million from Terumo Corporation, offset by non-recurring restructuring and closure charges, negative effects of foreign currency translation, increased income tax expense and fair value adjustments of certain investments recorded during the period.

###

Media Contact***Biosensors International Group***

Mr. Loh Chee Mun

Senior Vice President

Tel: (65) 6213 5712

Email: media@biosensors.com

Media Relations / Investor Relations Firm**United States*****Allen & Caron Inc.***

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stents and open-heart surgery. It has two separate drug-eluting stent programs, BioMatrix™ and BioFreedom™, a completely polymer-free drug-eluting stent.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.